National Cancer Control Programmes

Policies and managerial guidelines

World Health Organization
Geneva
1995
## Contents

Preface \hspace{1cm} vii  
Acknowledgements \hspace{1cm} ix  
Executive summary \hspace{1cm} xiii  
Introduction \hspace{1cm} 1

### Part I. The scientific basis of national cancer control programmes

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>The nature of cancer</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Biological aspects of cancer</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Social aspects of cancer</td>
<td>10</td>
</tr>
<tr>
<td>2.</td>
<td>The causes of cancer</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Biological factors in cancer etiology</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>External agents important for cancer control</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Physical carcinogens</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Chemical carcinogens</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Biological carcinogens</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Dietary influences</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Social factors in cancer etiology</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Relative importance of various causes of cancer</td>
<td>19</td>
</tr>
<tr>
<td>3.</td>
<td>Extent, distribution, and trends of cancer</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Cancer as a world health problem</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Cancer of various sites in different countries</td>
<td>24</td>
</tr>
</tbody>
</table>
Cancer trends over time 25
Social and economic impacts of cancer 26

Part II. Approaches to cancer control 27

4. Introduction 29

5. Primary prevention 30
   Tobacco 30
   Diet 39
   Alcohol 43
   Occupation and environment 47
   Infections and cancer 52
   Sunlight 53
   Sexual and reproductive factors 55

6. Early detection of cancer 58
   Education for early diagnosis 58
   Screening for cancer 61

7. Treatment of cancer 70
   Aims and limitations of treatment for cancer 71
   Development of a treatment policy 76
   Development of referral policies 77
   Ethical aspects of cancer therapy 78
   Evaluation of effectiveness of treatment 80

8. Palliative care 82

9. Cancer control research 87

Part III. Establishing and managing national cancer control programmes 89

10. Establishing a national cancer control programme 91
    Assessing the magnitude of the cancer challenge 92
    Prevention policy 97
    Integration with national health programming 98
    Intersectoral aspects of cancer control 99

iv
CONTENTS

Setting measurable cancer control objectives 100
Evaluating possible strategies for cancer control 103
Choosing priorities for initial cancer control activities 104
Political will for cancer control 105

11. Managing the establishment of a national cancer control programme 106
Planning the NCCP 106
Establishing the NCCP 107
Launching the NCCP with a workshop 107
Developing a communication strategy 108
Recruiting leaders 108
Consideration of existing health care systems 109
Consultation with nongovernmental organizations 109
Ensuring community involvement 110
Preparing a draft national cancer control plan 110
Organizing a national conference 110
Changing legislation 111
Identifying resources for the NCCP 111
Reviewing the role of existing organizations in cancer control 111
Identifying the systems that already exist 112
Drawing up a budget for cancer control 113

12. Implementing and maintaining a national cancer control programme 115
Functions of the NCCP 115
Management activities in the NCCP 116
The NCCP coordinator 116
The NCCP management board 117
Fund-raising 117
Creating an identity for the NCCP 117
Evaluation of the NCCP 118

13. Monitoring and evaluating components of the national cancer control programme 119
Prevention 121
Early detection of cancer 121
Treatment 122
Palliative care 122

References 123
Annexes
1. Calculation of expected age-specific mortality rates in different regions 128
2. Outline agenda for a workshop on national cancer control programmes 129
3. Example of a programme for a national cancer control workshop 131
4. Evaluation of a national cancer control programme 134
Cancer is an increasingly important item on every country’s health agenda. Medical knowledge is now sufficiently advanced to allow the prevention of at least one-third of all cancers, the cure of a further third provided that there is early diagnosis, and adequate symptom control (palliative care) of the remainder. Putting this knowledge into effect for the control of cancer, however, requires the establishment of systematic programmes on a national basis.

This handbook aims to provide guidance on the development of national cancer control programmes (NCCPs). It is therefore directed primarily at policy-makers in health and related fields, but will also be of interest to health ministries and academic institutions and, more generally, to individuals who need to keep abreast of developments in cancer control. It is additionally intended as a concise statement of what is feasible and desirable in cancer control in terms of putting science into practice.

The timeliness of this publication is underlined by the fact that the World Health Organization’s programme on NCCPs, developed over the past 12 years, is about to be expanded on the basis of experience gained in the countries that have already, with WHO assistance, established such programmes. Moreover, WHO Member States, in their work towards health for all by the year 2000, are continuing to formulate and implement national health strategies, of which plans for cancer control must form an increasing part.

A preliminary version of this handbook was produced following the meeting of a Working Group on National Cancer Control Programmes, 25-29 November 1991, at WHO headquarters in Geneva, Switzerland. It was initiated and edited by Anthony B. Miller (visiting scientist, Cancer and Palliative Care, WHO) and Jan Stjernswärd (Chief, Cancer and Palliative Care, WHO). Two earlier reports served as a basis for its preparation, one drafted by Lester Breslow (School of Public Health and Jonsson Comprehensive Cancer
NATIONAL CANCER CONTROL PROGRAMMES

Center, University of California, Los Angeles, CA, USA) and the other written by the editors. The final version was produced following the meeting of a Working Group on National Cancer Control Programmes in Banff, Alberta, Canada, 26 September–1 October 1993.

More than 40 countries have already instituted NCCPs or received comprehensive grounding in their principles and operation. The target for the year 2000 is for this number to exceed 100; some programmes will serve as demonstration projects, with carefully monitored and evaluated indicators for implementation.

Jan Stjernswärd
Chief
Cancer and Palliative Care
World Health Organization
Acknowledgements

The valuable contributions made by the following participants in the meeting of the WHO Working Group on National Cancer Control Programmes (Geneva, 25–29 November 1991) are gratefully acknowledged:

Mr W.A. Adair, Cancer 2000, Toronto, Canada
Dr K. Anantha, Kidwai Memorial Institute of Oncology, Bangalore, India
Dr B. Armstrong, International Agency for Research on Cancer, Lyon, France
Dr H. Barnum, World Bank, Washington, DC, USA
Dr J.M. Borras, Department of Health and Social Security, Government of Catalonia, Barcelona, Spain
Dr L. Breslow, Center for Health Promotion/Disease Prevention, School of Public Health, Los Angeles, CA, USA
Dr R. Camacho, National Institute of Cancer and Radiobiology, Havana, Cuba
Dr H. Danielsson, Cancer and Palliative Care, World Health Organization, Geneva, Switzerland
Dr L. Fernandez, National Institute of Cancer and Radiobiology, Havana, Cuba
Dr J.A.M. Gray, Oxfordshire Department of Public Health, Headington, England
Dr J.D.F. Habbema, Department of Public Health and Social Medicine, Erasmus University, Rotterdam, Netherlands
Dr T. Hakulinen, Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland
Dr R.C. Hickey, International Union Against Cancer, Geneva, Switzerland
Dr M.K.M. Ismail, Tanta Cancer Institute, Cairo, Egypt
Dr N.A. Jafarey, College of Physicians and Surgeons, Karachi, Pakistan
NATIONAL CANCER CONTROL PROGRAMMES

Dr L.M. Jerry, Alberta Cancer Program, Calgary, Canada
Dr C.F. Kiire, WHO Regional Office for Africa, Brazzaville, Congo
Dr L. Komarova, Cancer Research Centre, Moscow, Russian Federation
Dr V. Korolchouk, Cancer and Palliative Care, World Health Organization, Geneva, Switzerland
Dr G. Llanos, WHO Regional Office for the Americas, Washington, DC, USA
Dr A. Lopez, Global Health Situation Assessment and Projection, World Health Organization, Geneva, Switzerland
Dr U. Luthra, Indian Council for Medical Research, New Delhi, India
Dr J. Magrath, National Cancer Institute, Bethesda, MD, USA
Dr R. Margolese, Jewish General Hospital, Montreal, Canada
Dr A. Mbakop, University of Yaoundé, Yaoundé, Cameroon
Dr T.R. Möller, Southern Swedish Regional Tumour Registry, University Hospital, Lund, Sweden
Dr K. Nair, Regional Cancer Centre, Trivandrum, India
Dr E.J. Ospina, Pathology Clinic Palermo, Bogotá, Colombia
Dr A. Roxas, Department of Health, Philippine Cancer Control Programme, Manila, Philippines
Dr V. Sagaidak, Division of Cancer Control, Cancer Research Centre, Moscow, Russian Federation
Dr H. Sell, WHO Regional Office for South-East Asia, New Delhi, India
Dr C. Sepulveda, Ministry of Health, Santiago, Chile
Dr T.F. Solanke, National Headquarters of Cancer Registries in Nigeria, University College Hospital, Ibadan, Nigeria
Dr R. Sweet, Commission of the European Communities, Brussels, Belgium
Dr Tan Chor-Hiang, Ministry of Health, Singapore
Dr N. Trapeznikov, Cancer Research Centre, Moscow, Russian Federation
Ms M. Truax, Nursing, World Health Organization, Geneva, Switzerland
Mr A.J. Turnbull, International Union Against Cancer, Geneva, Switzerland
Dr M.H. Wahdan, WHO Regional Office for the Eastern Mediterranean, Alexandria, Egypt
Dr L. Waldström, Oncological Centre for Southern Sweden, University Hospital, Lund, Sweden
Dr B. Wasisto, Ministry of Health, Jakarta, Indonesia
Dr F. Zdra, European School of Oncology, Milan, Italy
ACKNOWLEDGEMENTS

Dr S.H.M. Zaidi, Jannah Postgraduate Medical Centre, Karachi, Pakistan

Similar acknowledgements are due for the contributions made by the following participants in the second Working Group on National Cancer Control Programmes (Banff, 26 September–1 October 1993):

Dr M. Al-Jarallah, Kuwait Cancer Control Centre, Kuwait
Dr H.G. Al-Jazzaf, Kuwait Cancer Control Centre, Kuwait
Dr A. Alwan, WHO Regional Office for the Eastern Mediterranean, Alexandria, Egypt
Dr C. Atkinson, Christchurch Hospital, Christchurch, New Zealand
Dr J. Bauer, Charles University, Prague, Czech Republic
Mr H. Barnum, World Bank, Washington, DC, USA
Dr C. Bratti, Health Directorate, San José, Costa Rica
Dr R. Calderon-Saniz, Ministry of Social Welfare and Public Health, La Paz, Bolivia
Dr R. Camacho Rodriguez, National Institute of Cancer and Radiobiology, Havana, Cuba
Ms S. Dahl, Ministry of Health, Wellington, New Zealand
Mr T.K. Das, Ministry of Health and Family Welfare, New Delhi, India
Dr T.D. Devaraj, National Cancer Society of Malaysia, Penang, Malaysia
Dr J. Fins, Cornell Medical Center, New York, NY, USA
Mr W. Foster, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Dr P. Géher, Ministry of Welfare, Budapest, Hungary
Professor M.A. Hai, Cancer Institute and Research Hospital, Mohakhali, Dhaka, Bangladesh
Mrs E. Henry, New South Wales Cancer Council, Wallsend, New South Wales, Australia
Dr E. Hill, Department of Health, London, England
Dr L.-E. Holm, National Institute of Public Health, Stockholm, Sweden
Dr M.A. Jaffer, Ministry of Health, Muscat, Oman
Dr M. Jerry, WHO Collaborating Centre for Cancer Control, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Dr E.A.R. Kaegi, National Cancer Institute of Canada, Toronto, Ontario, Canada
Dr M. Kasler, National Institute of Oncology, Budapest, Hungary
Dr V. Koroltchouk, Cancer and Palliative Care, World Health Organization, Geneva, Switzerland
Dr R. Lappi, National Research and Development Centre, Helsinki, Finland
Dr J.M. Larranaga, Health Ministry, Montevideo, Uruguay
Dr M. Laugesen, Public Health Commission, Wellington, New Zealand
Dr A. Legaspi, Juarez Hospital, Cuahulemo, Mexico
Dr F. Li, Laboratory Centre for Disease Control, Health Canada, Ottawa, Ontario, Canada
Dr T.J. Liebenberg, Cancer Association of South Africa, Johannesburg, South Africa
Dr R.R. Love, University of Wisconsin, Madison, WI, USA
Dr N. MacDonald, University of Alberta, Edmonton, Alberta, Canada
Dr S.S. Manraj, Central Health Laboratory, Quatre-Bornes, Mauritius
Dr B. Mashbadrakh, National Centre of Oncology, Ulaanbaatar, Mongolia
Dr B. Mathew, Regional Cancer Centre, Trivandrum, India
Ms P. Messervy, Ministry of Health, Wellington, New Zealand
Dr H. Mustun, Victoria Hospital, Candos, Mauritius
Dr M.K. Nair, Regional Cancer Centre, Trivandrum, India
Dr J. Ospina, International Union Against Cancer, Santa Fé de Bogotá, Colombia
Dr S. Puribhat, National Cancer Institute, Bangkok, Thailand
Dr B. Randeniya, Cancer Institute, Maharagama, Sri Lanka
Dr A. Roxas, Philippines Cancer Control Program, Manila, Philippines
Dr R. Sanson-Fisher, New South Wales Cancer Council, Wallsend, New South Wales, Australia
Dr H. Schipper, St Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada
Dr C. Sepulveda, Ministry of Health, Santiago, Chile
Dr T.F. Solanke, National Headquarters of Cancer Registries in Nigeria, Ibadan, Nigeria
Dr S. Stachenko, Health Canada, Ottawa, Ontario, Canada
Dr H. Storm, Danish Cancer Society, Division of Cancer Epidemiology, Copenhagen, Denmark
Dr G. Stuart, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Dr F.C.M. Sungani, National Cancer Committee, Blantyre, Malawi
Dr Tan Chor-Hiang, Ministry of Health, Singapore
Dr E. W. Trevelyan, Harvard School of Public Health, Boston, MA, USA
Dr B.B. Vaidya, B.P. Koirala Memorial Cancer Hospital, Kathmandu, Nepal
Dr Z. Zain, Ministry of Health, Kuala Lumpur, Malaysia
Dr M.P. Zakelj, Institute of Oncology, Ljubljana, Slovenia
Executive summary

This handbook outlines the scientific knowledge that is the basis for national cancer control programmes (NCCPs) and offers extensive guidance on their establishment and organization. Much of its content derives from experience gained in the various countries that have already—with assistance from the World Health Organization—instituted their own NCCPs.

Cancer annually affects 9 million people and causes 5 million deaths. In developed countries it is the second most common cause of death, and epidemiological evidence points to the emergence of a similar trend in developing countries. The principal factors contributing to this disease pattern are the increasing proportion of elderly people (in whom cancer is more prevalent) in most populations, the greater ability of medical science to control once-fatal communicable diseases, and the rising incidence of certain forms of cancer, notably lung cancer resulting from tobacco use. It is likely that 300 million new cases of cancer and 200 million deaths from the disease will occur in the next 25 years, with almost two-thirds of cases arising in developing countries.

Medical advances mean that one-third of all cancers are preventable and a further one-third, if diagnosed sufficiently early, are potentially curable. Moreover, appropriate palliative care of the remaining one-third of cancer patients can bring about substantial improvements in the quality of life. With careful planning and appropriate priorities, the establishment of NCCPs offers the most rational means of achieving this degree of cancer control, even where resources are severely limited.

When cancer is diagnosed, it is a natural reaction to seek to cure the condition, and increasingly effective treatment strategies indeed make cure possible in certain cases. However, undue reliance on this approach, which often involves the use of sophisticated and expensive techniques, can result in inequitable selection of patients, rapid depletion of scarce resources, and a shift in emphasis away from much more appropriate and affordable prevention activities.
The nature of cancer

The term cancer is used generically for some 100 different diseases including malignant tumours of different sites (breast, cervix, prostate, stomach, colon/rectum, lung, mouth, etc.), leukaemia, sarcoma of bone, Hodgkin disease, and non-Hodgkin lymphoma. Common to all forms of the disease is the failure of the mechanism that regulates normal cell growth and proliferation; ultimately, there is progression of the resulting uncontrolled growth from mild to severe abnormality, with invasion of neighbouring tissues and, eventually, spread to other areas of the body.

The disease arises principally as a consequence of the conditions of life—exposure of individuals to carcinogenic agents in the atmosphere and in what they eat and drink. Personal habits such as tobacco use, frequently developed in response to social circumstances, and occupational exposure to carcinogens play a particularly significant role in the etiology of cancer, as may biological factors such as viral hepatitis B infection. Many of these factors can be exploited as a means of cancer control; vaccination against hepatitis B, for instance, can protect against liver cancer.

Prevention of cancer

The present and potential burden of tobacco-induced cancer is such that every country should give immediate priority to tobacco control in its fight against cancer: tobacco use in all forms is responsible for about 30% of all cancer deaths in developed countries and a rapidly rising proportion in developing countries. The habit of tobacco use is reinforced by physiological dependence on nicotine, and cigarette smoking in particular is encouraged by the marketing activities of national and multinational tobacco companies. Unchecked, smoking will cause more than 10 million deaths from cancer (predominantly lung cancer) in the next decade.

Dietary modification is another approach to cancer control. In recent years, substantial evidence has pointed to a causative role of excessive dietary fat in certain cancers, and to a protective effect of increased consumption of whole grains, fruit, and vegetables. Moreover, eating habits that may inhibit the development of diet-associated cancers will also lower the risk of cardiovascular disease.

Occupational and environmental exposure to a number of chemicals can cause cancer of a variety of sites; examples include lung cancer (asbestos), bladder cancer (aniline dyes), and leukaemia (benzene). Excessive consumption of alcohol increases the risk of cancer of the oral cavity, pharynx, and oesophagus, and is strongly associated with cancer of the liver in developed countries. Strong links also exist between a number of infections and certain types of cancer: viral hepatitis B is linked with
cancer of the liver, and human papilloma virus infection with cervical cancer. In some countries the parasitic infection schistosomiasis significantly increases the risk of bladder cancer. Exposure to some forms of ionizing radiation and to excessive ultraviolet radiation—particularly from the sun—is also known to give rise to certain cancers, notably of the skin.

The wealth of knowledge that already exists about these predisposing factors provides obvious and ample scope for action to reduce the cancer burden of all countries.

**Early detection of cancer**

The earlier a cancer is detected and diagnosed, the greater is the chance that curative treatment will be successful; this is particularly true of cancers of the breast, cervix, mouth and skin. It is therefore critical that people are taught to recognize early signs of the disease, such as lumps, sores that fail to heal, abnormal bleeding, persistent indigestion, and chronic hoarseness, and urged to seek prompt medical attention. This can be promoted in all countries by public health education campaigns and through training of primary health workers.

Population screening, i.e. mass application of simple tests to identify individuals with asymptomatic disease, is another approach to early detection. However, screening programmes should be undertaken only where their effectiveness has been demonstrated, where resources (personnel, equipment, etc.) are sufficient to cover at least 70% of the target group, where facilities exist for confirming diagnoses and for treatment and follow-up of those with abnormal results, and where prevalence of the disease is high enough to justify the effort and costs of screening. At present, mass screening can be advocated only for cancer of the breast and cervix. Efforts should concentrate on women at greatest risk of developing invasive cancer, i.e. those aged 35 and over for cervical cancer and those aged over 50 for mammography programmes for breast cancer.

**Treatment of cancer**

The primary objectives of cancer treatment are cure, prolongation of life, and improvement of the quality of life. An NCCP should therefore establish guidelines for integrating treatment resources with programmes for screening and early diagnosis, and provide therapeutic standards for the most important cancers in the country.

Care of cancer patients typically starts with recognition of abnormality, followed by consultation at a health care facility with appropriate services
for diagnosis and treatment. If necessary, there should be referral to a specialized cancer treatment centre. Treatment may involve surgery, radiation therapy, chemotherapy, hormonal therapy, or some combination of these.

The most advanced forms of treatment may produce a 5-year survival rate of 75% or more in certain types of cancer, e.g. cancer of the uterine corpus, breast, and testis, and melanoma. By contrast, survival rates in cancer of the pancreas, liver, stomach, and lung are generally less than 15%. Some treatments require sophisticated technology that is available only in locations with substantial resources. Since the cost of establishing and maintaining such facilities is high, it is desirable that they should remain concentrated in relatively few places in a country to avoid draining resources that could valuably be devoted to other aspects of the NCCP’s work.

**Palliative care**

Improved quality of life is of paramount importance to patients with cancer, and pain relief and palliative care must therefore be regarded as integral and essential elements of an NCCP, whatever the possibilities of cure. Since they can be provided relatively simply and inexpensively, they should be available in every country and should continue to be given high priority, especially in developing countries where cure of the majority of cancer patients is likely to remain impossible for years to come. Health professionals should be trained to deliver palliative care, both within health-care facilities and in patients’ homes. Guidelines for the relief of cancer pain have been drawn up by, and are available from, WHO; the widespread availability of morphine for oral administration is critical to pain relief, and should be ensured by appropriate legislation.

**National policies for cancer control**

The development of national policies for cancer control depends upon assessing the extent to which the population is affected by cancer, determining the factors responsible for the disease, and identifying means of dealing with the problem. The essential data can be obtained from cancer registries where these have been established, but are also available from other sources.

Policies should take account of the resources that can be devoted to proposed activities, and programmes should be undertaken only if they fulfil the criteria of scientifically demonstrable value, acceptability to the population concerned, and financial feasibility. In the long run, pre-
ventive activities are more effective and much less costly than efforts to treat the disease. Policies should therefore make provision for:

- controlling tobacco use by various means, including mass education, tax increases, and restrictions on sales and places of use;
- evaluation of dietary intake of fats, fruits, and vegetables, and promoting the adoption and maintenance of healthy diets;
- alerting the public to the cancer risks of certain communicable and sexually transmitted diseases, and promoting appropriate measures such as vaccination against viral hepatitis B infection;
- identification of carcinogens to which people are exposed, and legislation for their control.

The relative importance of the various forms of cancer in the country concerned should be considered. The national cancer control strategy should incorporate measures for prevention, early diagnosis, and treatment, and should be based on comprehensive analysis of the existing situation, including a review of the causes of these cancers and of the resources available to deal with the problem.

Greatest effectiveness is achieved by integration of cancer control into a country’s overall health service, with coordinated action on the risk factors that are shared with other diseases. The health infrastructure can be used for mass education about the nature of the disease, its causes and manifestations, and about what preventive action can be taken by the individual (with regard to diet and alcohol and tobacco use) and by society as a whole (control of tobacco availability and use and of occupational and environmental exposure to carcinogens). Policies should cover the training and continuing education of primary health workers in the prevention and early detection of cancer, and in referral of patients to appropriate diagnostic and treatment services.

Policies for cancer control should also extend beyond the health sector to include relevant activities in the fields of education, agriculture, industry, and commerce. Where possible, economic incentives for minimizing cancer hazards should be provided in industry and agriculture.

Establishing an NCCP

There are four basic steps to the establishment of an NCCP—assessing the magnitude of the national cancer problem, setting measurable objectives for control of the disease, evaluating possible control strategies, and choosing priorities for initial control activities.

If no reliable national data are available, it may be assumed that background cancer incidence is in the range 100–180 per 100 000. The
lower level is likely to represent the situation in a country with more than half its population under 20 years of age, and the upper level a country in which a maximum of one-third of the population is under 20. Where awareness of cancer is low and access to health care severely limited, few of the actual cases of cancer (perhaps only 5–10%) will be known to the health service. As awareness increases, so will demands for care and thus the burden on health service resources.

The options for cancer control appropriate to a particular country should be examined from a number of perspectives, such as the prevalence of the 10 most common forms of cancer, the level at which care will be provided (primary health care or hospital care), the stage of intervention (prevention, early diagnosis, treatment, palliative care), the general concerns of the public, management activities (e.g. information systems), and political and planning concerns. Assessment of the current situation should be initiated through the ministry of health in collaboration with nongovernmental organizations active in cancer control; advisers with expertise in cancer control should be consulted as necessary.

It is envisaged that the process of establishing an NCCP should include launch of the programme with a workshop, development of a communication strategy, appointment of an NCCP coordinator, preparation of a draft national cancer control plan, determination of the part already being played in cancer control by existing organizations, identification of new and existing resources for the NCCP, setting of priorities, and formulation of a specific budget for cancer control. Managerial expertise is essential in the areas of implementation of the programme, fund-raising, public education, professional education and development, information systems, quality assurance, research and policy development, and evaluation.

Knowledge gained over the past two decades provides enormous scope for controlling cancer throughout the world, and the most appropriate mechanism for exploiting that knowledge is through the establishment of national cancer control programmes.
Noncommunicable diseases, which are on the increase throughout the world, are expected to be the cause of 54% of all deaths in the year 2015; tropical infections and parasitic diseases, by contrast, will account for only 16% of deaths—a marked fall from the 1985 figure of 35%. Cancer is currently the cause of one-tenth of all deaths, and is the second most frequent cause of death in the majority of developed countries. The disease has often been regarded as a problem belonging principally to the developed world; in fact, more than half of all cancers occur among the three-quarters of the world's people who live in the developing countries (I).

Although cancer can occur at any age, it is more common in older people. As the proportion of elderly people increases in most countries, and tobacco use and exposure to other carcinogens grow, the burden of cancer will rise significantly. Recent trends indicate that, without rigorous control measures, cancer will become the leading cause of death in many countries during the early part of the next century, with 300 million new cancer cases and 200 million deaths from cancer over a 25-year period. Almost two-thirds of all cancers will occur in the developing countries, which have only 5% of the resources for cancer control. At present, of an estimated 9 million new cancer cases each year, 4 million are in developed and 5 million in developing countries; in approximately 25 years' time, these figures are likely to reach 15, 5 and 10 million, respectively (see Table 1). In other words, an increase of 25% will take place in developed countries, compared with 100% in the developing world. Approximately 17.5 million people are alive with cancer at present; by 2015 there will probably be more than 30 million.

The upward trend of cancer incidence in developing countries mirrors that observable wherever societies become increasingly urbanized/industrialized, and is probably the result more of demographic and social changes than of industrialization per se.
NATIONAL CANCER CONTROL PROGRAMMES

Table 1. Numbers of cancer deaths and new cancer cases in the world as estimated for 1985 and predicted for 2015

<table>
<thead>
<tr>
<th>Year</th>
<th>Region</th>
<th>Deaths (millions)</th>
<th>New cases (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1985</td>
<td>Developed countries</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Developing countries</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>All countries</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>2015</td>
<td>Developed countries</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Developing countries</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>All countries</td>
<td>9</td>
<td>15</td>
</tr>
</tbody>
</table>

Efforts to reverse this trend, and to make optimum use of resources to put research findings into practice are likely to fail unless they are properly coordinated. National cancer control programmes (NCCPs) offer the best means of reconciling what is possible with what is achievable in particular circumstances.

Cancer control covers a broad spectrum, from primary prevention, through early detection and screening, treatment, and rehabilitation, to palliative care. The word “control” does not imply that cancer can be eradicated in the way that an infectious disease can be eradicated, by immunization, but that control can be exercised over its causes and consequences: the concept of cancer control empowers society to achieve mastery over the disease. The magnitude of the cancer problem, and its growing importance in almost all countries, coupled with the clinical knowledge now available, compel the development of national strategies for cancer control. There is little evidence so far of a balanced use of resources for population-wide control of cancer by governmental and nongovernmental bodies acting in partnership, yet the means exist to prevent between a third and a half of the 9 million cancer cases that occur annually throughout the world. Current knowledge would also allow the early diagnosis and effective treatment of a further one-third of those cases, and pain relief and palliative care to improve the quality of life of patients whose cancer is incurable.

Because the individual patient with cancer seeks help from medical practitioners, the problem of the disease tends to be widely viewed as one of fulfilling treatment needs. With national planning and coordination, however, another approach becomes possible—that of intervention to minimize the incidence of cancer. Similar approaches to other health problems, such as tuberculosis and infant mortality,
have met with marked success. Thus, national policy should embrace not only cancer treatment but also the measures that can be taken, by the individual as much as by the government, to prevent the occurrence of the disease.

While large areas of ignorance still remain, enough is known about the causes of cancer and means of control for suitable interventions to have significant impact. At least one-third of the 9 million new cases of cancer each year are preventable by such means as controlling tobacco and alcohol use, and immunizing against viral hepatitis B. Early diagnosis, and therefore treatment, of a further one-third of cases (for example, cancer of the cervix, cancer of the breast) are possible where resources allow. Effective techniques for pain relief are sufficiently well established to permit comprehensive palliative care in the remaining, more advanced, cases. The most rational and effective means of implementing these measures is through an NCCP, which can achieve optimum use of resources by setting realistic priorities and instituting appropriate strategies.

An NCCP may be defined as a process that leads to the development of a comprehensive, integrated national or regional programme with specific, measurable intermediate and outcome objectives and strategies for the balanced use of resources for cancer control. Ideally, the process of establishing an NCCP should be organized, democratic, empowering, and pragmatic, with the boundaries of the programme defined by the social, medical, and political environment of the country concerned.

In the absence of any national coordinating mechanism, it is possible for limited resources to be largely consumed in the treatment of cancer by prestigious hospitals. Such institutions often serve only selected populations and do little to reduce the national cancer burden. An effective cancer control programme, on the other hand, is an integrated set of activities covering primary prevention, early diagnosis and treatment, and palliative care, and operates with appropriate allocation of available resources.

The NCCP should be approved and endorsed by the ministry of health, and all its basic measures, such as legislation to control tobacco use or to ensure the availability of morphine for oral administration in palliative care, should be undertaken at national level. In large countries and countries where there is significant state or provincial autonomy, however, it may be appropriate for many elements of the programme to be administered on a state or provincial basis. All sectors of the population should be covered by the provisions of an NCCP: few countries have the resources to do all that is theoretically possible to control cancer, but equitable distribution
of resources can be achieved by coordinating activities through the NCCP.

Over many years, WHO has supported a number of countries in establishing NCCPs (2–6), and worked out general policies on primary prevention, early diagnosis, screening, health care personnel, and palliative care, as well as a method of achieving cost-effectiveness in cancer control (7–17). Parts I and II of this handbook summarize the scientific basis for national cancer control programmes, and Part III sets out the steps involved in instituting such programmes.